Cannabidiol as a potential treatment for psychosis

Eur Neuropsychopharmacol. 2014 Jan;24(1):51-64. doi: 10.1016/j.euroneuro.2013.11.002. Epub 2013 Nov 15.


Although cannabis use is associated with an increased risk of developing psychosis, the cannabis constituent cannabidiol (CBD) may have antipsychotic properties. This review concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of currently available animal, human experimental, imaging, epidemiological and clinical studies that investigated the antipsychotic properties of CBD. In this targeted literature review we performed a search for English articles using Medline and EMBASE. Studies were selected if they described experiments with psychosis models, psychotic symptoms or psychotic disorders as outcome measure and involved the use of CBD as intervention. Evidence from several research domains suggests that CBD shows potential for antipsychotic treatment.

Keywords: Antipsychotics; Cannabidiol; Cannabis; Psychosis; Schizophrenia; Treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antipsychotic Agents / therapeutic use*
  • Cannabidiol / therapeutic use*
  • Databases, Bibliographic / statistics & numerical data
  • Humans
  • Psychotic Disorders / drug therapy*


  • Antipsychotic Agents
  • Cannabidiol